Pfizer Avoids Settlements, Scores Third Patent Victory In As Many Months
Executive Summary
Pfizer completed a patent litigation hat trick with its successful defense of a generic challenge to Norvasc, proving itself an exception to the recent industry trend of settling patent suits
You may also be interested in...
Pfizer Continues Slow Exubera Roll-Out, Wants To Grow Chantix Market
Exubera goes to primary care in 2007: Pfizer will roll out its inhaled insulin Exubera to general practitioners starting in January, the company said; patient and physician education programs limited to endocrinologists began in July (1"The Pink Sheet" July 24, 2006, p. 3). Compensation for sales reps will also change in January: Reps "were incentivized to educate rather than drive volume," Pfizer Head of U.S. Pharmaceutical Operations Peter Brandt said Oct. 19 during the firm's third quarter earnings call. "We are going to be driving more of the volume out of the next wave of our rollout going to the GP community"...
Pfizer Continues Slow Exubera Roll-Out, Wants To Grow Chantix Market
Exubera goes to primary care in 2007: Pfizer will roll out its inhaled insulin Exubera to general practitioners starting in January, the company said; patient and physician education programs limited to endocrinologists began in July (1"The Pink Sheet" July 24, 2006, p. 3). Compensation for sales reps will also change in January: Reps "were incentivized to educate rather than drive volume," Pfizer Head of U.S. Pharmaceutical Operations Peter Brandt said Oct. 19 during the firm's third quarter earnings call. "We are going to be driving more of the volume out of the next wave of our rollout going to the GP community"...
Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition
The Federal Trade Commission will not remain complacent as brand and generic companies accelerate the pace and expand the boundaries of settlements, Commissioner Jon Leibowitz said